AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24769555 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold (Absorb BVS) system
Number of subjects: 512
Study 24770443 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) procedures
Number of subjects: 42
Study 24770461 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise task
Number of subjects: 74
Study 24770461 — intervention group
Group type: EXPERIMENTAL
Intervention: Feels-good task (self-selected intensity)
Number of subjects: 74
Study 24770971 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-PCA with ethanol and paclitaxel
Number of subjects: 22
Study 24771206 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0
Study 24771206 — intervention group
Group type: COMPARATOR
Intervention: Active painkillers followed by placebos
Number of subjects: 0
Study 24771206 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors and social support
Number of subjects: 0
Study 24771206 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down systems for pain control
Number of subjects: 0
Study 24771206 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain imaging studies
Number of subjects: 0
Study 24771350 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP9521 (30 mg/day for 12 weeks)
Number of subjects: 13
Study 24771806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexfin™ device
Number of subjects: 31
Study 24772351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Number of subjects: 678
Study 24772351 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 678
Study 24773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma samples using allele-specific PCR assays
Number of subjects: 199
Study 24773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy samples using cobas(®) EGFR Tissue Test
Number of subjects: 199
Study 24773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched pairs of plasma and biopsy samples
Number of subjects: 199
Study 24773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma samples
Number of subjects: 199
Study 24773774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and biopsy tissue comparison
Number of subjects: 199
Study 24773782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HEV IgG antibodies
Number of subjects: 166
Study 24773782 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent HEV infection
Number of subjects: 166
Study 24773782 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV RNA detection
Number of subjects: 166
Study 24773782 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of HEV infection
Number of subjects: 166
Study 24773782 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of recent infection (acute on chronic) liver disease
Number of subjects: 166
Study 24774037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion excision and decompression of Guyon's canal
Number of subjects: 9
Study 24774647 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma folate concentrations
Number of subjects: 709
Study 24774647 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin B12 concentrations
Number of subjects: 709
Study 24774647 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate increase
Number of subjects: 709
Study 24774647 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS scores
Number of subjects: 709
Study 24775515 — intervention group
Group type: EXPERIMENTAL
Intervention: Travelers who acquired multiresistant Enterobacteriaceae
Number of subjects: 2216
Study 24777136 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic medication
Number of subjects: 0
Study 24777136 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy surgery (selective amygdalohippocampectomy, temporal lobe resection)
Number of subjects: 0
Study 24777136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiofrequency amygdalohippocampectomy and hippocampal stimulation
Number of subjects: 0
Study 24777247 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells electroporated with mRNA coding for CAR
Number of subjects: 4
Study 24777247 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated infusions of CAR-T cells
Number of subjects: 4
Study 24777501 — intervention group
Group type: EXPERIMENTAL
Intervention: (124)I-labeled L19SIP (immuno-PET imaging)
Number of subjects: 6
Study 24777716 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks, 900 mg in week 5, and 900 mg every 2 weeks thereafter)
Number of subjects: 7
Study 24777850 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception prediction model for gestational diabetes mellitus (GDM)
Number of subjects: 326
Study 24777850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes in women with PCOS
Number of subjects: 326
Study 24777850 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal complications during pregnancy
Number of subjects: 326
Study 24777850 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal complications
Number of subjects: 326
Study 24778397 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-OPC patients
Number of subjects: 164
Study 24778397 — intervention group
Group type: COMPARATOR
Intervention: Partners of HPV-OPC patients
Number of subjects: 164
Study 24780049 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in BAT-positive women
Number of subjects: 401
Study 24780049 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in individuals with sarcopenia
Number of subjects: 401
Study 24780049 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in individuals defined by ASM/height(2)
Number of subjects: 401
Study 24780049 — intervention group
Group type: COMPARATOR
Intervention: Circulating irisin levels in individuals with detectable BAT
Number of subjects: 401
Study 24780049 — intervention group
Group type: COMPARATOR
Intervention: Circulating irisin levels in individuals with sarcopenia compared to control subjects
Number of subjects: 401
Study 24780882 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded allele size for SCA2 and SCA3 genotypes
Number of subjects: 1310
Study 24780882 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded allele size for SCA1 and SCA6 genotypes
Number of subjects: 1310
Study 24780882 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal allele size for SCA1 and SCA6 genotypes
Number of subjects: 1310
Study 24780907 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing in patients with mild-to-moderate PV stenosis
Number of subjects: 19
Study 24780907 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear increase of peak PV gradient with increasing flow
Number of subjects: 19
Study 24780907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen pulse-workload relationship
Number of subjects: 19
Study 24780907 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart morphology and function assessment
Number of subjects: 19
Study 24780909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve area (AVA) adjusted by body surface area (BSA)
Number of subjects: 2843
Study 24780909 — intervention group
Group type: COMPARATOR
Intervention: Aortic valve area (AVA)
Number of subjects: 2843
Study 24781896 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Aerobic Cardiovascular Endurance Run (PACER) laps (aerobic fitness)
Number of subjects: 687
Study 24781896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness (measured by PACER)
Number of subjects: 687
Study 24781896 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 687
Study 24782475 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior iris-claw aphakic IOL implantation and DMEK
Number of subjects: 7
Study 24782509 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR.CD19-T cells expanded ex vivo using IL-2
Number of subjects: 14
Study 24782509 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturing CAR-T cells with IL-7 and IL-15
Number of subjects: 14
Study 24782549 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional breathing (UB)
Number of subjects: 16
Study 24782620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansenula-derived PEGylated interferon alpha-2a plus ribavirin for 12 weeks (weekly subcutaneous injection of PEG-IFN-alpha-2a plus daily oral ribavirin).
Number of subjects: 46
Study 24782620 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment course up to 72 weeks for patients who were PCR-negative at week 48 but had at least one PCR-positive test during therapy.
Number of subjects: 46
Study 24782620 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment schedule of PEG-IFN-alpha-2a plus ribavirin.
Number of subjects: 46
Study 24782620 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to better response: male gender, short duration of infection, low viral load, mild activity, and mild fibrosis.
Number of subjects: 46
Study 24782620 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of liver transaminases before and after treatment.
Number of subjects: 46
Study 24782684 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBFA-HIIT (3 g per day of HMBFA)
Number of subjects: 34
Study 24782684 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA-HIIT
Number of subjects: 34
Study 24782684 — intervention group
Group type: COMPARATOR
Intervention: CTL
Number of subjects: 34
Study 24784775 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT
Number of subjects: 27
Study 24786393 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (IST) consisting of antithymocyte globulin and cyclosporine A in 28 patients
Number of subjects: 92
Study 24786393 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRVβ skewing in 40% of RCC patients
Number of subjects: 92
Study 24786594 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Thermometer (patient-reported health status instrument)
Number of subjects: 408
Study 24786603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg BID) combined with radiation therapy (60 Gy in 2 Gy fractions) and temozolomide (75 mg/m² daily)
Number of subjects: 17
Study 24786603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg BID) combined with radiation therapy and temozolomide
Number of subjects: 17
Study 24786603 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 17
Study 24786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2936
Study 24786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2936
Study 24786834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2936
Study 24786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (both doses)
Number of subjects: 2936
Study 24786929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously every 2 weeks
Number of subjects: 40
Study 24787738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (500 mg, once daily) for 1 or 2 days followed by oral azithromycin (250 mg once daily) to complete a total of 7 days treatment
Number of subjects: 60
Study 24788740 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24788804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Empowerment Programme (PEP)
Number of subjects: 1141
Study 24788804 — intervention group
Group type: COMPARATOR
Intervention: non-PEP group
Number of subjects: 1141
Study 24788898 — intervention group
Group type: EXPERIMENTAL
Intervention: PrePex device
Number of subjects: 427
Study 24788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection education workbook with pictures of skin cancer on varying skin tones
Number of subjects: 24
Study 24788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised workbook including pictures of squamous cell carcinoma
Number of subjects: 24
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional T lesion (insufficient collateral flow to ipsilateral anterior cerebral arteries via contralateral ICA)
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional L lesion
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional I lesion
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clots categorized as I lesion
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clots categorized as L lesion
Number of subjects: 72
Study 24789707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clots categorized as T lesion
Number of subjects: 72
Study 24789750 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous cyanoacrylate-based embolization
Number of subjects: 38
Study 24790273 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea syndrome (OSAS) screening using ≥ 3/h total sleep time (TST) as the cutoff.
Number of subjects: 248
Study 24790273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean respiratory disturbance index (RDI) assessment.
Number of subjects: 248
Study 24790273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean obstructive RDI (ORDI) assessment.
Number of subjects: 248
Study 24790273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean obstructive apnea-hypopnea index (OAHI) assessment.
Number of subjects: 248
Study 24790820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 79
Study 24790820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LFD)
Number of subjects: 79
Study 24792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem biopsy
Number of subjects: 0
Study 24793253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes at hospital discharge using SF-12, Hospital Anxiety and Depression Scale, EQ-5D, Brief Illness Perception Questionnaire (B-IPQ), HeartQoL, and Edmonton Symptom Assessment Scale.
Number of subjects: 0
Study 24793253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes at baseline.
Number of subjects: 0
Study 24794216 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (OCR)
Number of subjects: 1001
Study 24794216 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-aspirin platelet reactivity (OAR)
Number of subjects: 1001
Study 24794216 — intervention group
Group type: COMPARATOR
Intervention: High vs. normal on-treatment platelet reactivity
Number of subjects: 1001
Study 24794806 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR103168, a novel multi-targeted kinase inhibitor
Number of subjects: 29
Study 24794816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (2-8 g oral) for 5 days and 8 weeks, with doses gradually escalated during phases 1 and 2.
Number of subjects: 0
Study 24794816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (3.5-6 g daily) for 8 weeks.
Number of subjects: 0
Study 24794816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (high-dose)
Number of subjects: 0
Study 24794816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Number of subjects: 0
Study 24794878 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 24795390 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein farnesylation inhibitors (treated group)
Number of subjects: 86
Study 24795390 — intervention group
Group type: COMPARATOR
Intervention: Untreated cohort (control group)
Number of subjects: 86
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IL-6 level at year 1
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sTNFR-I level at year 1
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sTNFR-II level at year 1
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher KT ratio at year 1
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher D-dimer level at year 1
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker values at baseline and pre-event time points
Number of subjects: 0
Study 24795473 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell activation
Number of subjects: 0
Study 24795483 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hookworm infection with Necator americanus
Number of subjects: 0
Study 24796940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 40
Study 24796940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 40
Study 24797180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-toxicity conditioning (RTC) regimen of BU 12.8-16 mg/kg, fludarabine 180 mg/m², alemtuzumab 54 mg/m² (BFA) before HLA-matched sibling donor transplantation
Number of subjects: 18
Study 24797299 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prognostic index based on 8 independent predictors of overall survival (OS) including sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum β2-microglobulin, and serum thymidine kinase.
Number of subjects: 1948
Study 24797299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index validated in a series of 676 newly diagnosed CLL patients from Mayo Clinic.
Number of subjects: 1948
Study 24797373 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of spiritual care providers (supporting religious and spiritual needs, providing support for family feelings)
Number of subjects: 275
Study 24797373 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of spiritual care providers (discussions about patient's end-of-life wishes, preparation for family conference, total number of activities performed)
Number of subjects: 275
Study 24798021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral posaconazole with intravenous micafungin bridging (POS-MIC)
Number of subjects: 212
Study 24798021 — intervention group
Group type: COMPARATOR
Intervention: Oral posaconazole (POS)
Number of subjects: 212
Study 24799460 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive patients
Number of subjects: 64
Study 24799460 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 64
Study 24799460 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative patients
Number of subjects: 64
Study 24799460 — intervention group
Group type: COMPARATOR
Intervention: p16-negative patients
Number of subjects: 64
Study 24799460 — intervention group
Group type: COMPARATOR
Intervention: Loss of ≥5% weight in previous 6 months
Number of subjects: 64
Study 24799481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with rituximab and anthracycline
Number of subjects: 125
Study 24799481 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual uptake higher than MBP but below liver uptake
Number of subjects: 125
Study 24799481 — intervention group
Group type: EXPERIMENTAL
Intervention: Using liver uptake as cutoff for PET positivity
Number of subjects: 125
Study 24800110 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention (motivational interview + Internet program)
Number of subjects: 83
Study 24800110 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention (brief advice + Internet program)
Number of subjects: 83
Study 24800110 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention
Number of subjects: 83
Study 24800110 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 24800123 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 20
Study 24800123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24800949 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m², Pazopanib 400 mg, Lapatinib 1000 mg
Number of subjects: 26
Study 24800949 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m² with Pazopanib 400 mg and Lapatinib 1000 mg
Number of subjects: 26
Study 24801171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 20
Study 24801350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expanding metal stents (FCSEMS)
Number of subjects: 187
Study 24801465 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher zinc and copper concentrations in cord blood
Number of subjects: 240
Study 24801465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower activity of glutathione peroxidase enzyme 3 in umbilical cord blood plasma
Number of subjects: 240
Study 24801465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and E concentrations in plasma
Number of subjects: 240
Study 24801544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-inspired artificial pancreas (BiAP) system during fasting study
Number of subjects: 20
Study 24801544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-inspired artificial pancreas (BiAP) system during overnight/postprandial study
Number of subjects: 20
Study 24801836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral and intramuscular injections of polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (poly-ICLC)
Number of subjects: 1
Study 24802773 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg, days 5-32) + Dexamethasone (40 mg by mouth, days 1-4)
Number of subjects: 12
Study 24805101 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with anti-CD3
Number of subjects: 53
Study 24805101 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated lung CD4+ T cells
Number of subjects: 53
Study 24805101 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of subjects
Number of subjects: 53
Study 24807459 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib (7.5 mg and 12.5 mg) in combination with carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²)
Number of subjects: 12
Study 24807459 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib (12.5 mg)
Number of subjects: 12